227 related articles for article (PubMed ID: 34454967)
1. Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction.
Harries I; Berlot B; Ffrench-Constant N; Williams M; Liang K; De Garate E; Baritussio A; Biglino G; Plana JC; Bucciarelli-Ducci C
Int J Cardiol; 2021 Nov; 343():180-186. PubMed ID: 34454967
[TBL] [Abstract][Full Text] [Related]
2. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
[TBL] [Abstract][Full Text] [Related]
3. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
4. Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes.
Park HS; Hong YJ; Han K; Kim PK; An E; Lee JY; Park CH; Lee HJ; Hur J; Kim YJ; Choi BW
J Cardiovasc Magn Reson; 2021 Jun; 23(1):76. PubMed ID: 34134713
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of anthracycline-induced myocardial injury using serial cardiac magnetic resonance: An animal study.
Wang R; Zhou Z; Schoepf UJ; Varga-Szemes A; Strigenz A; Wang H; Liu Y; Xu L
Int J Cardiol; 2021 Apr; 328():111-116. PubMed ID: 33359332
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.
Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058
[TBL] [Abstract][Full Text] [Related]
7. Late effects of pediatric hematopoietic stem cell transplantation on left ventricular function, aortic stiffness and myocardial tissue characteristics.
Paiman EHM; Louwerens M; Bresters D; Westenberg JJM; Tao Q; van der Geest RJ; Lankester AC; Roest AAW; Lamb HJ
J Cardiovasc Magn Reson; 2019 Jan; 21(1):6. PubMed ID: 30651110
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer.
Thavendiranathan P; Shalmon T; Fan CS; Houbois C; Amir E; Thevakumaran Y; Somerset E; Malowany JM; Urzua-Fresno C; Yip P; McIntosh C; Sussman MS; Brezden-Masley C; Yan AT; Koch CA; Spiller N; Abdel-Qadir H; Power C; Hanneman K; Wintersperger BJ
JAMA Cardiol; 2023 Jun; 8(6):524-534. PubMed ID: 37043251
[TBL] [Abstract][Full Text] [Related]
9. Early myocardial oedema can predict subsequent cardiomyopathy in high-dose anthracycline therapy.
Muehlberg F; Kornfeld M; Zange L; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
ESC Heart Fail; 2023 Feb; 10(1):616-627. PubMed ID: 36404640
[TBL] [Abstract][Full Text] [Related]
10. Prospective multiparametric CMR characterization and MicroRNA profiling of anthracycline cardiotoxicity: A pilot translational study.
Harries I; Biglino G; Ford K; Nelson M; Rego G; Srivastava P; Williams M; Berlot B; De Garate E; Baritussio A; Liang K; Baquedano M; Chavda N; Lawton C; Shearn A; Otton S; Lowry L; Nightingale AK; Carlos Plana J; Marks D; Emmanueli C; Bucciarelli-Ducci C
Int J Cardiol Heart Vasc; 2022 Dec; 43():101134. PubMed ID: 36389268
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
[TBL] [Abstract][Full Text] [Related]
12. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity.
Lambert J; Lamacie M; Thampinathan B; Altaha MA; Esmaeilzadeh M; Nolan M; Fresno CU; Somerset E; Amir E; Marwick TH; Wintersperger BJ; Thavendiranathan P
Heart; 2020 Jun; 106(11):817-823. PubMed ID: 32098808
[TBL] [Abstract][Full Text] [Related]
13. Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors.
Mawad W; Mertens L; Pagano JJ; Riesenkampff E; Reichert MJE; Mital S; Kantor PF; Greenberg M; Liu P; Nathan PC; Grosse-Wortmann L
Eur Heart J Cardiovasc Imaging; 2021 Mar; 22(4):435-442. PubMed ID: 32535624
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular magnetic resonance parametric techniques to characterize myocardial effects of anthracycline therapy in adults with normal left ventricular ejection fraction: a systematic review and meta-analysis.
Musella F; Librera M; Sibilio G; Boccalatte M; Tagliamonte G; Cavaglià E; Ferrara I; Puglia M; Dell'Aversana S; Ducci CB; Dellegrottaglie S; Savarese G; Scatteia A
Curr Probl Cardiol; 2024 Jul; 49(7):102609. PubMed ID: 38697332
[TBL] [Abstract][Full Text] [Related]
15. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.
Toro-Salazar OH; Gillan E; O'Loughlin MT; Burke GS; Ferranti J; Stainsby J; Liang B; Mazur W; Raman SV; Hor KN
Circ Cardiovasc Imaging; 2013 Nov; 6(6):873-80. PubMed ID: 24097420
[TBL] [Abstract][Full Text] [Related]
16. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling.
Tham EB; Haykowsky MJ; Chow K; Spavor M; Kaneko S; Khoo NS; Pagano JJ; Mackie AS; Thompson RB
J Cardiovasc Magn Reson; 2013 Jun; 15(1):48. PubMed ID: 23758789
[TBL] [Abstract][Full Text] [Related]
17. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity.
Higgins AY; Arbune A; Soufer A; Ragheb E; Kwan JM; Lamy J; Henry M; Cuomo JR; Charifa A; Gallegos C; Hull S; Coviello JS; Bader AS; Peters DC; Huber S; Mojibian HR; Sinusas AJ; Kluger H; Baldassarre LA
PLoS One; 2021; 16(2):e0246764. PubMed ID: 33606757
[TBL] [Abstract][Full Text] [Related]
18. Time-dependent cardiac structural and functional changes after kidney transplantation: a multi-parametric cardiac magnetic resonance study.
Qi L; Ni X; Schoepf UJ; Varga-Szemes A; McGill L; Wang W; Zhang L; Luo S; Wen J; Zhang LJ
Eur Radiol; 2022 Aug; 32(8):5265-5275. PubMed ID: 35275257
[TBL] [Abstract][Full Text] [Related]
19. Test-retest reliability of left and right ventricular systolic function by new and conventional echocardiographic and cardiac magnetic resonance parameters.
Houard L; Militaru S; Tanaka K; Pasquet A; Vancraeynest D; Vanoverschelde JL; Pouleur AC; Gerber BL
Eur Heart J Cardiovasc Imaging; 2021 Sep; 22(10):1157-1167. PubMed ID: 32793957
[TBL] [Abstract][Full Text] [Related]
20. Long-term prognostic value of right ventricular dysfunction on cardiovascular magnetic resonance imaging in anthracycline-treated cancer survivors.
Chhikara S; Hooks M; Athwal PSS; Hughes A; Ismail MF; Joppa S; Velangi PS; Nijjar PS; Blaes AH; Shenoy C
Eur Heart J Cardiovasc Imaging; 2022 Aug; 23(9):1222-1230. PubMed ID: 34297807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
